Cochrane · systematic review · CD006573
Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation
Gurusamy, KS, Tsochatzis, E, Toon, CD, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
5
No studies
4
Included studies
NR
No studies 4 · 44.4%Ungraded 0 · 0%Very low 5 · 55.6%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation (mortality)
Population: patients undergoing liver transplantation for chronic hepatitis C viral infection.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Interferon vs. control | no estimate extracted | NR | No studies |
90‐day mortality | RR 1.31 [0.41, 4.19] | 1 study · 81 participants | Very low Downgraded: risk of bias |
Mortality at maximal | RR 0.86 [0.36, 2.08] | 2 studies · 105 participants | Very low Downgraded: risk of bias |
Mortality (HR) | HR 0.45 [0.13, 1.56] | 1 study · 81 participants | Very low Downgraded: risk of bias |
HCV antibody vs. placebo | no estimate extracted | NR | No studies |
Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation (retransplantation)
Population: patients undergoing liver transplantation for chronic hepatitis C viral infection.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Interferon vs. control | no estimate extracted | NR | No studies |
Retransplantation at maximal | RR 1.17 [0.22, 6.2] | 2 studies · 105 participants | Very low Downgraded: risk of bias |
HCV antibody vs. placebo | no estimate extracted | NR | No studies |
90‐day retransplantation | RR 1.71 [0.09, 32.93] | 1 study · 18 participants | Very low Downgraded: risk of bias |